Stage-Specific Characterization of the Vascular Endothelial Growth Factor Axis in Prostate Cancer: Expression of Lymphangiogenic Markers Is Associated with Advanced-Stage Disease
The DOI matches its Crossref record.
Abstract
Purpose: The vascular endothelial growth factor (VEGF) family plays a critical role in tumor angiogenesis and lymphangiogenesis. We characterized, at the mRNA and protein levels, the expression of VEGF-A and VEGF-D and their cognate receptors, VEGFR-1, VEGFR-2, and VEGFR-3 in early- and advanced-stage prostate cancer specimens. Experimental Design: The levels of VEGF-A and VEGF-D mRNA in early- and advanced-stage specimens were compared using an angiogenic gene array and were confirmed by quantitative real-time PCR. Receptor protein levels and activation status were determined by immunoblotting. Spatial expression of the proteins was evaluated using immunohistochemistry with fresh and archival tissues from benign prostatic hypertrophy specimens, early-stage prostate specimens, and advanced-stage metastatic specimens. Circulating plasma levels of these growth factors were measured using ELISAs. Results: We observed that expression patterns of VEGF isotypes corresponded to the prostate cancer stage: high expression of angiogenic growth factor VEGF-A was observed in early-stage prostate specimens, whereas high expression of lymphangiogenic growth factor VEGF-D was associated with advanced-stage metastatic disease. All VEGF receptors were present at variable levels in all specimens, but their activation states varied in a stage-specific manner. VEGFR-1 and, to a limited extent, VEGFR-2 were activated in early-stage specimens, whereas VEGFR-2 and VEGFR-3 were activated in advanced-stage specimens. Conclusions: Our results suggest that lymphangiogenic markers, such as VEGF-D and VEGFR-2 and VEGFR-3, may be better than angiogenic markers as targets of therapeutic intervention in advanced-stage prostate disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The VEGF-C/Flt-4 axis promotes invasion and metastasis of cancer cells
Su, J.-L., Yang, P.-C., Shih, J.-Y., Yang, C.-Y., Wei, L.-H., Hsieh, C.-Y., Chou, C.-H., Jeng, Y.-M., Wang, M.-Y., Chang, K.-J., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.02.018 · Cited by 348
Hsu, M.-C., Pan, M.-R., & Hung, W.-C. (2019) · Cells · doi:10.3390/cells8030270 · Cited by 67
Expression of Tissue Factor in Prostate Cancer Correlates With Malignant Phenotype
Kaushal, V., Mukunyadzi, P., Siegel, E. R., Dennis, R. A., Johnson, D. E., & Kohli, M. (2008) · Applied Immunohistochemistry & Molecular Morphology · doi:10.1097/01.pai.0000213157.94804.fc · Cited by 32
Self-citationTakao, A., Yoshikawa, K., Karnan, S., Ota, A., Uemura, H., De Velasco, M., Kura, Y., Suzuki, S., Ueda, R., Nishino, T., et al. (2018) · Oncology Reports · doi:10.3892/or.2018.6683 · Cited by 26
Metadata
- Authors
- Kaushal, V., Mukunyadzi, P., Dennis, R. A., Siegel, E. R., Johnson, D. E., & Kohli, M.
- Venue
- Clinical Cancer Research
- Published
- 2005-01-15
- Volume
- 11
- Issue
- 2
- Pages
- 584-593
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2108151385
- Cited by
- 76
- References
- 0
- FWCI
- 3.96
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Stage-Specific Characterization of the Vascular Endothelial Growth Factor Axis in Prostate Cancer: Expression of Lymphangiogenic Markers Is Associated with Advanced-Stage Disease. https://app.cochat.ai/papers/10.1158/1078-0432.584.11.2
- The paper
- Kaushal, V., Mukunyadzi, P., Dennis, R. A., Siegel, E. R., Johnson, D. E., & Kohli, M. (2005). Stage-Specific Characterization of the Vascular Endothelial Growth Factor Axis in Prostate Cancer: Expression of Lymphangiogenic Markers Is Associated with Advanced-Stage Disease. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.584.11.2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.